Compare SG & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SG | ATXS |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.7M | 722.1M |
| IPO Year | 2021 | 2015 |
| Metric | SG | ATXS |
|---|---|---|
| Price | $6.64 | $12.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 6 |
| Target Price | $15.75 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 7.9M | 992.4K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $685,184,000.00 | $706,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $17.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.43 | N/A |
| 52 Week Low | $5.14 | $3.56 |
| 52 Week High | $42.65 | $12.72 |
| Indicator | SG | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 66.95 |
| Support Level | $6.27 | $12.55 |
| Resistance Level | $6.99 | $12.69 |
| Average True Range (ATR) | 0.42 | 0.19 |
| MACD | 0.14 | -0.11 |
| Stochastic Oscillator | 82.13 | 86.21 |
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.